jan-20 The stock still is a buy given the catalysts coming up, including the January 20 announcement, possible share buy-backs, and the company's plan to do some acquisitions.
However, near-term share price performance will depend on how management performs in its meetings with fund managers. Confidence among institutional players is lacking and has to be Nobilis Health is still suffering a lack of investor confidence despite clearing up most of the uncertainties about its financial reporting and guidance.
The numbers the company plans to release on January 20 -- namely 2015 preliminary estimates and 2016 guidance -- will be important in helping to restore confidence.
This is all critical for the company's future growth plans because it has said it needs a higher stock price to do the large acquisitions that shareholders expect
.